Key result
Antidepressants show no significant difference versus placebo for ventricular arrhythmias and sudden cardiac death.
Why the study?
Data regarding the risk of ventricular arrhythmia and sudden cardiac death associated with commonly prescribed antidepressants were limited.
Do different classes of antidepressants (TCA, SNRI, SSRI) differ in their risk of ventricular arrhythmia and sudden cardiac death?
Meta-Analysis (n=5,682,348)
Do different classes of antidepressants (TCA, SNRI, SSRI) differ in their risk of ventricular arrhythmia and sudden cardiac death?
A network meta-analysis suggests a low risk of ventricular arrhythmia and sudden cardiac death among patients using antidepressants, with TCAs ranking as having the lowest risk compared to SNRIs and SSRIs.
Answers are grounded in this paper and cite their sources.
May support low VA/SCD risk with antidepressants; extends meta-analytic data but wide CIs leave confirmation open.
Background: Antidepressants are one of the most prescribed medications, particularly for patients with mental disorders. Nevertheless, there are still limited data regarding the risk of ventricular arrhythmia (VA) and sudden cardiac death (SCD) associated with these medications. Thus, we performed systemic review and meta-analysis to characterize the risks of VA and SCD among patients who used common antidepressants. Methods: A literature search for studies that reported risk of ventricular arrhythmias and sudden cardiac death in antidepressant use from MEDLINE, EMBASE, and Cochrane Database from inception through September 2020. A random-effects model network meta-analysis model was used to analyze the relation between antidepressants and VA/SCD. Surface Under Cumulative Ranking Curve (SUCRA) was used to rank the treatment for each outcome. Results: The mean study sample size was 355,158 subjects. Tricyclic antidepressant (TCA) patients were the least likely to develop ventricular arrhythmia events/sudden cardiac deaths at OR 0.24, 0.028–1.2, OR 0.32 (95% CI 0.038–1.6) for serotonin and norepinephrine reuptake inhibitors (SNRI), and OR 0.36 (95% CI 0.043, 1.8) for selective serotonin reuptake inhibitors (SSRI), respectively. According to SUCRA analysis, TCA was on a higher rank compared to SNRI and SSRI considering the risk of VA/SCD. Conclusion: Our network meta-analysis demonstrated the low risk of VA/SCD among patients using antidepressants for SNRI, SSRI and especially, TCA. Despite the relatively lowest VA/SCD in TCA, drug efficacy and other adverse effects should be taken into account in patients with mental disorders.
No takes yet. Share an insight, caveat, or question.
Prasitlumkum et al. (2021) conducted a meta-analysis in Patients prescribed common antidepressants (n=5,682,348). Tricyclic antidepressants (TCA) vs. Placebo was evaluated on Ventricular arrhythmia events / sudden cardiac deaths (OR 0.24, 95% CI 0.028-1.2). Tricyclic antidepressants (OR 0.24), SNRIs (OR 0.32), and SSRIs (OR 0.36) were associated with a comparatively low risk of ventricular arrhythmia and sudden cardiac death compared to placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: